Guanhao Biotech(SZ:300238)2025-09-19 10:04Group 1: Financial Performance and Dividend Policy - The company has not distributed dividends for 7 consecutive years due to negative distributable profits, which complies with relevant regulations [3][18] - The management is focused on improving operational efficiency and resource allocation to meet future dividend conditions [7][18] - The company emphasizes the importance of shareholder returns and plans to develop a cautious dividend policy based on actual profit distribution conditions [3][18] Group 2: Core Business Areas - The company focuses on three main business segments: materials, pharmaceuticals, and cell therapy [3][11] - Key products in the materials segment include biological dura mater patches and sterile biological dressings, applicable in various medical fields [3][11] - The pharmaceutical segment features products like Bimekizumab, which treats inflammatory and autoimmune diseases [3][11] Group 3: Research and Development Progress - The company is actively advancing research in stem cell therapy and has ongoing projects in various medical fields, including liver disease and skin conditions [5][9] - The biological artificial liver project is currently in the preclinical research stage [9][18] - The company collaborates with several hospitals for clinical studies in areas such as cartilage repair and severe psoriasis treatment [5][9] Group 4: Market and Investor Relations - The company acknowledges the need for improved communication with investors regarding clinical results and project updates [6][9] - There are no current plans for share buybacks, but the company will adhere to regulations if such plans arise in the future [9][18] - The management is committed to maintaining transparency and fulfilling information disclosure obligations as required by regulations [6][9]